41 results about "HTERT Gene" patented technology

A reversibly immortalized human pancreatic islet cell line containing an hTERT gene and an SV40T gene each interposed between a pair of LoxP sequences, characterized in that it is capable of producing insulin and enhancing expression of insulin after excising the hTERT gene and the SV40T gene, in particular, NAKT-13 (deposited with International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, address: AIST Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566 Japan, deposited date: Sep. 4, 2003, accession number: FERM BP-08461) or a passage cell line thereof; a human pancreatic islet cell obtained by excising the hTERT gene and the SV40T gene from the reversibly immortalized human pancreatic islet cell line or passage cell line thereof; and use of these cells. By using the reversibly immortalized human pancreatic islet cell line of the invention insulin-producing cells can be easily and surely obtained in a number enough to meet the demand.

The present invention relates to a method for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter. The method uses reaction compositions that comprise amplification primers and genotyping probes. Another aspect of this invention relates to the primers and probes used to implement the aforementioned method, with sequences, identified as SEQ ID no.1 to SEQ ID no.6, that displayhigh specificity for these mutations, and to the compositions containing these primers and probes. The present invention further relates to a kit comprising the above-mentioned compositions for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter by carrying out the method according to the present invention. The method, gene sequences, compositions and kit of the present invention can be advantageously used for detecting trace amounts of c.-124 C>T and c.-146 C>T mutations in biological samples, due to their high sensitivity and specificity for such mutations. The present invention can thus be applied in early detection, identification, detection of recurrence or prediction and monitoring of diseases associated with this type of mutations, such as bladder carcinomas, thyroid carcinomas, squamous cell carcinomas, basal cell carcinomas, melanomas, gliomas and hepatocellular carcinomas, inter alia, and ultimately provide the basis for defining a suitable treatment. Thus, the present invention pertains to the technical fields of medicine, pharmaceutics, molecular biology, biochemistry, human genetics and the like.

Reversibly immortalized human islet cell lines containing an hTERT gene and an SV40T gene each located between a pair of LoxP sequences, characterized by being capable of producing insulin and the expression of insulin being enhanced after removing the hTERT gene and the SV40T gene, in particular, NAKT-13 (having been deposited with International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, Address: Tsukuba Central 6, Higashi 1-1-1, Tsukuba, Ibaraki, 305-8566 JAPAN, Deposition date: 04 September, 2003, Deposition No.: FERM BP-08461) or passage cell lines thereof; human islet cells obtained by removing the hTERT gene and the SV40T gene from the reversibly immortalized human islet cell lines or passage cell lines thereof as described above; and use of these cells. By using the reversibly immortalized human islet cell lines as described above, insulin-producing cells can be easily and surely obtained in a number enough to meet demand.

The invention discloses a method to transduce full material stem cell among marrow with human end particle enzyme gene, which comprises the following steps: enzyme-cutting pGRN145 plasmid with Hpa I and Not I restriction enzymes; getting hTERT cDNA fragment; connecting to pLXSN carrier with the same restriction enzymes; constructing pLXSN-hTERT retooling expressing carrier; using LipofectAMINE liposome transduction agent box; preparing pLXSN-hTERT retooling expressing carrier floated liquid through compatible eating property incasing line PA317; proceeding transduction for full material stem cell among marrow; constructing the stem cell with high effective expressing exogenesis hTERT gene; double-sieving with low density homomycin; getting the stem cell. This invention can reach the goal to increase life cycle of full cytoplasma stem cell among marrow.

The present invention relates to an indolinone compound, which is 1-(4-chlorobenzyl)-3-(hydroxyimino)-4-(4-(trifluoromethyl)phenyl)indoline-2 ‑ketone, which can effectively inhibit the activity of hTERT gene promoter, semi-quantitative PCR experiments and Western blot experiments show that this compound can effectively inhibit the transcription and expression of hTERT, and more importantly, this compound can effectively reduce the length of telomeres in HeLa cells. MTT assay and plate clone assay showed that the compound could inhibit the viability and proliferation of HeLa cells. DAPI staining experiment and flow cytometry analysis showed that the compound could promote cell apoptosis. These results all indicate that the compound can target and inhibit the expression of hTERT and can be used as a new antitumor drug.